Non-formulary ezetimibe-simvastatin (Vytorin®) will be covered on the prescription drug benefit when the following criteria are met:

Clinical ASCVD or high ASCVD risk as defined by 10-year ASCVD risk of 7.5% or greater

– AND –

Receiving recommended statin intensity therapy or maximally tolerated doses of statin

– AND –

Receiving a statin + ezetimibe as 2 separate agents

Please Note:
* Preferred therapeutic options are:
  1) High intensity or maximally tolerated formulary statin doses
  2) Moderate intensity statin + ezetimibe as separate agents (generic co-pay)

* Evidence is lacking to support whether there is a difference between moderate intensity statin plus ezetimibe and high intensity statin monotherapy in reducing ASCVD events in any population.

* Additionally, there is a lack of evidence to support that addition of ezetimibe to high intensity statins further reduces ASCVD events or whether ezetimibe added to low intensity statins reduces clinical events in patients who are unable to tolerate moderate intensity statins.